Paraneoplastic pemphigus associated with non-Hodgkin B-cell lymphoma and good response to prednisone

被引:18
作者
De Pablo, MIM
Iranzo, P
Mascaró, JM
Llambrich, A
Baradad, M
Herrero, C
机构
[1] Univ Barcelona, IDIBAPS, Dept Dermatol, Clin Hosp,Serv Dermatol, ES-08036 Barcelona, Spain
[2] Arnau Vilanova Hosp, Dept Dermatol, Lleida, Spain
关键词
lymphoma; bullous disease; paraneoplastic; therapy;
D O I
10.1080/00015550510025542
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Paraneoplastic pemphigus is a life-threatening autoimmune bullous disease associated with neoplasia, generally of lymphoid origin. Immunosuppressive therapy is often disappointing and there are only a few reports of patients surviving more than 2 years. These cases were generally associated with benign neoplasms. We report here the case of a patient with paraneoplastic pemphigus associated with non-Hodgkin B-cell lymphoma who had a surprisingly good response to systemic corticosteroids and remains free of lesions more than 3 years later despite progression of her neoplasm.
引用
收藏
页码:233 / 235
页数:3
相关论文
共 50 条
  • [21] Large B-cell non-Hodgkin's lymphoma presenting as a laryngeal cyst
    Agada, FO
    Mistry, D
    Grace, ARH
    Coatesworth, AP
    JOURNAL OF LARYNGOLOGY AND OTOLOGY, 2005, 119 (08) : 658 - 660
  • [22] Expression levels of TWIST1 are associated with the clinicopathological stage of B-cell non-Hodgkin lymphoma
    Jia, Cundong
    Liang, Liping
    Yang, Lili
    Zhao, Feng
    Bai, Jingping
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2014, 8 (05) : 1489 - 1493
  • [23] Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children
    Giulino-Roth, Lisa
    Goldman, Stanton
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (04) : 531 - 544
  • [24] Beyond Rituximab: The Future of Monoclonal Antibodies in B-Cell Non-Hodgkin Lymphoma
    Sikder, Manzurul A.
    Friedberg, Jonathan W.
    CURRENT ONCOLOGY REPORTS, 2008, 10 (05) : 420 - 426
  • [25] Therapeutic targets and investigated strategies for treating B-cell non-Hodgkin lymphoma
    Villasboas, Jose C.
    Ansell, Stephen M.
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (08): : 921 - 932
  • [26] Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma
    Manzurul A. Sikder
    Jonathan W. Friedberg
    Current Oncology Reports, 2008, 10
  • [27] Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphoma
    Mohty, Razan
    Vanegas, Yenny Moreno
    Chavez, Julio C.
    Kharfan-Dabaja, Mohamed A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (02) : 121 - 126
  • [28] Persistent Intermediate Uveitis Associated with Latent Manifestation of Facial Large B-Cell Non-Hodgkin Lymphoma
    Sabet-Peyman, E. Jason
    Eberhart, Charles G.
    Janjua, Kashif
    Shah, Syed Mahmood
    Do, Diana V.
    Nguyen, Quan Dong
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2009, 17 (05) : 322 - 324
  • [29] Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma
    Sikder M.A.
    Friedberg J.W.
    Current Hematologic Malignancy Reports, 2008, 3 (4) : 187 - 193
  • [30] Autonomic dysfunction in Hodgkin and non-Hodgkin lymphoma. A paraneoplastic syndrome?
    Bilora, Franca
    Veronese, Francesco
    Zancan, Alice
    Biasiolo, Michela
    Pomerri, Fabio
    Muzzio, Pier Carlo
    HEMATOLOGY REPORTS, 2010, 2 (01) : 44 - 45